Phase Forward sets up own subsid in India

3 December 2007

Phase Forward, a USA-based provider of data management solutions for clinical trials and drug safety, has announced the establishment of a wholly-owned subsidiary, Phase Forward Software Services India, based in Hyderabad. In building this affiliate, Phase Forward will be working with current partner Virtusa Corp, a global information technology services company. The US firm's Hyderabad center will be situated within Virtusa's facilities.

Phase Forward has a long and successful track record in the Indian market, having worked with several partners and sponsors in the region for the last seven years to support several hundred hosted clinical trials. "The Indian market is strategic to Phase Forward's continued growth," said the firm's chief executive Bob Weiler. "The formation of a Phase Forward subsidiary in India is a natural extension of our long-established strategy to give our customers access to the most advantageous and cost-effective mix of offshore and onshore resources available. Since India is such a high-growth area for the biopharma services industry, we wanted to expand our commitment to the region by adding our own employees to our partner resources in the region," he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight